Potential mechanisms of action of antiviral agents.
D000547:Amantadine / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001380:Azauridine / Q000494:pharmacology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology; D012321:DNA-Directed RNA Polymerases / Q000096:biosynthesis; D003857:Deoxyuridine / Q000494:pharmacology; D006566:Herpesviridae Infections / Q000188:drug therapy; D006801:Humans; D007065:Idoxuridine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007372:Interferons / Q000494:pharmacology; D014176:Protein Biosynthesis / Q000187:drug effects; D012367:RNA, Viral / Q000096:biosynthesis; D012194:RNA-Directed DNA Polymerase / Q000096:biosynthesis; D012293:Rifampin / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology; D013310:Streptovaricin / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013882:Thiosemicarbazones / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014616:Vaccinia virus / Q000187:drug effects
D000998:Antiviral Agents; D012367:RNA, Viral; D012294:Rifamycins; D013882:Thiosemicarbazones; D003561:Cytarabine; D013310:Streptovaricin; D001380:Azauridine; D007372:Interferons; D000547:Amantadine; D012194:RNA-Directed DNA Polymerase; D012321:DNA-Directed RNA Polymerases; D007065:Idoxuridine; D012293:Rifampin; D003857:Deoxyuridine